{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"47","value":"51.30"},{"groupId":"OG001","spread":"20","value":"36.49"}]}],"title":"Day -7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18","value":"20.43"},{"groupId":"OG001","spread":"25","value":"14.44"}]}],"title":"Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) of midazolam was determined using linear/log trapezoidal method. Only participants in 25 mg and 150 mg QD groups were given midazolam. Day -7 data reflect the PK assessment before administration of PF-06463922, and Cycle 1 Day 15 data reflect the PK assessment after multiple doses of PF-06463922 were administered.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"PF-06463922 25 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.","id":"OG000","title":"25 mg QD (Phase 1)"},{"description":"PF-06463922 150 mg was orally given QD in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal. Midazolam 2 mg was orally given QD on Day -7 and Cycle 1 Day 15.","id":"OG001","title":"150 mg QD (Phase 1)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK parameter analysis set for midazolam included all participants who received at least 1 dose of midazolam and for which at least 1 midazolam PK parameter of interest was available.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","title":"Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam (Phase 1)","type":"SECONDARY","unitOfMeasure":"ng*hr/mL"}